Keyphrases
Population-based Study
100%
Young Adolescents
66%
Netherlands
66%
Preadolescent children
66%
Central Nervous System Tumors
46%
Young children
33%
Relapsed or Refractory Acute Myeloid Leukemia
33%
Infant Patients
33%
Gemtuzumab Ozogamicin
33%
Vidaza
33%
Azacitidine
33%
Pediatric Patients
33%
Population-based Cohort Study
33%
Sex-related
33%
Group Studies
33%
Juvenile Myelomonocytic Leukemia
33%
Phase II Study
33%
Glioma Subtypes
33%
Pediatric Glioma
33%
Survival Disparities
33%
Myelodysplastic Syndrome
33%
Survival Rate
33%
Children with Cancer
33%
Belgium
33%
Malignant Tumor
27%
Age Groups
23%
Pilocytic Astrocytoma
22%
Survival Outcomes
22%
Standardized Incidence Ratio
20%
Neuroblastoma
20%
Registration Practices
18%
Observed Survival
17%
Neutralizing Effect
16%
Incidence Characteristics
16%
Diffuse Glioma
16%
Tumor Characteristics
16%
Survival Characteristics
16%
Sex Differences
16%
Aging Characteristics
16%
Survival Gap
16%
High Risk
16%
Treatment Characteristics
16%
Acute Lymphoblastic Leukemia
13%
Minimal Residual Disease
13%
Confidence Interval
13%
Belgian
13%
Cancer Incidence
13%
Cancer Mortality
13%
Non-malignant Tumor
11%
Overall Survival
10%
Medicine and Dentistry
Central Nervous System Tumor
55%
Malignant Neoplasm
38%
Azacitidine
33%
Survival Rate
33%
Toddlers
33%
Inotuzumab Ozogamicin
33%
Myelodysplastic Syndrome
33%
Juvenile Myelomonocytic Leukemia
33%
Acute Lymphoblastic Leukemia
33%
Pediatrics Patient
33%
Adolescence
33%
Ganglioneuroblastoma
33%
Pediatric Cancer
33%
Pilocytic Astrocytoma
22%
Cancer Incidence
22%
Cancer Mortality
22%
Cancer Registry
16%
Hematopoietic Stem Cell Transplantation
13%
Minimal Residual Disease
13%
Neoplasm
11%
Acute Myeloid Leukemia
11%
Rhabdomyosarcoma
11%
Cancer
11%
Cancer Epidemiology
11%
Cancer Types
11%
Cancer Survival
11%
Overall Survival
10%
Disease
6%
Vein Occlusion
6%
Transplantation
6%
Allograft
6%
Pharmacokinetics
6%
Optic Nerve Tumor
5%
Deterioration
5%
Tumor of Central Nervous System
5%
Diagnosis
5%
Pediatrics
5%
Mortality Rate
5%
Pharmacology, Toxicology and Pharmaceutical Science
Central Nervous System Tumor
33%
Inotuzumab Ozogamicin
33%
Myelodysplastic Syndrome
33%
Azacitidine
33%
Acute Lymphoblastic Leukemia
33%
Juvenile Myelomonocytic Leukemia
33%
Survival Rate
33%
Malignant Neoplasm
23%
Pilocytic Astrocytoma
19%
Minimal Residual Disease
13%
Overall Survival
10%
Neoplasm
9%
Disease
6%
Remission
6%
Vein Occlusion
6%
Pharmacokinetics
6%
